Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective and randomized controlled study on the efficacy and safety of ipragliflozin and metformin to visceral fat reduction for the patients being treated with DPP-4 inhibitors for poor glycemic controlled type-2 diabetes

Next Previous
Search
Trial Profile

Prospective and randomized controlled study on the efficacy and safety of ipragliflozin and metformin to visceral fat reduction for the patients being treated with DPP-4 inhibitors for poor glycemic controlled type-2 diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipragliflozin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms PRIME-V

    • Most Recent Events

    • 29 Sep 2023 Results of sub-analysis comparing metabolomic changes associated with ipragliflozin and metformin that may contribute to their biological effects, published in the Pharmacotherapy
    • 23 Sep 2022 Results (N=30) evaluating metabolome analysis of the effects of ipragliflozin and metformin on human metabolites, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes..
    • 05 Oct 2018 Results comparing ipragliflozin and metformin for bone density and muscle in type 2 diabetes patients, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top